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CD45 is the prototypic member of transmembrane receptor-like protein tyrosine phosphatases 
(RPTPs) and has essential roles in immune functions. The cytoplasmic region of CD45, like 
many other RPTPs, contains two homologous protein tyrosine phosphatase domains, active 
domain 1 (D1) and catalytically impaired domain 2 (D2). Here, we report crystal structure of 
the cytoplasmic D1D2 segment of human CD45 in native and phosphotyrosyl peptide-bound 
forms. The tertiary structures of D1 and D2 are very similar, but doubly phosphorylated CD3
 
  
 
immunoreceptor tyrosine-based activation motif peptide binds only the D1 active site. The D2 
“active site” deviates from the other active sites significantly to the extent that excludes any 
possibility of catalytic activity. The relative orientation of D1 and D2 is very similar to that 
observed in leukocyte common antigen–related protein with both active sites in an open 
conformation and is restrained through an extensive network of hydrophobic interactions, 
hydrogen bonds, and salt bridges. This crystal structure is incompatible with the wedge model 
previously suggested for CD45 regulation.
 
Protein tyrosine phosphorylation is a key mech-
anism for nearly every aspect of cell regulation,
ranging from cell survival and proliferation to
apoptotic cell death in multicellular eukaryotes.
Tyrosine phosphorylation itself is regulated by a
concerted action of protein tyrosine kinases and
protein tyrosine phosphatases (PTPs). The hu-
man genome encodes as many as 38 classical
PTPs, which share highly homologous PTP
domains (1). These PTPs are divided into two
major subfamilies: 17 nonreceptor (or cyto-
plasmic) PTPs and 21 receptor-like (transmem-
brane) PTPs. CD45, also known as the leuko-
cyte common antigen, is the prototype of the
receptor-like PTP (RPTP) subfamily and is
found in all nucleated hematopoietic cells (2–4).
CD45 is essential for development and antigen-
induced activation of T and B cells (5–9). Mu-
tations in the human CD45 gene have been
associated  with SCID and multiple sclerosis
(10–12). CD45 controls immune response, both
positively and negatively, by dephosphorylating a
number of signaling molecules, including Src
family kinases (Lck and Fyn), the CD3
 
  
 
chain
of TCR, and ZAP-70 kinase (13, 14).
Like many other RPTPs, CD45 consists of
an extracellular receptor-like region, a short
transmembrane segment, and a cytoplasmic re-
gion comprising tandem PTP domains (see
Fig. 1 A). The length of the extracellular seg-
ment varies among the CD45 isoforms gener-
ated by alternative splicing (15). Mutational anal-
yses have shown that the membrane proximal
PTP domain 1 (D1), but not the membrane
distal domain 2 (D2), is catalytically active
(16). The entire cytoplasmic region of CD45 is
conserved among vertebrates, from shark to
mammalian (17). The strong conservation of
the CD45 D2 primary structure implies a
functional role, but this role is not yet clearly
defined. Nonetheless, there are observations
that suggest a regulatory role of the catalytically
inert D2 domain (18). D2 perhaps influences the
activity of D1 by direct intermolecular and in-
tramolecular interaction, as shown by in vitro
binding studies (19, 20). Phosphorylation of
D2 by casein kinase 2 enhances the phos-
phatase activity of D1, consistent with a regu-
latory role of the D2 domain (21). It was also
reported that the CD45 D2 domain could, by
itself, bind one of the important substrates,
Lck, facilitating its dephosphorylation by D1
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domain (22). In the case of another RPTP, leukocyte com-
mon antigen–related (LAR) protein, we observed a high de-
gree of similarity between the crystal structures of the D1
and D2 domains (23). Perhaps consistent with the structural
similarity of D2 and D1, only two amino acid substitutions
were required to convert the otherwise inert D2 domains of
LAR and PTP
 
  
 
into active enzymes (23–25). These findings
led us to propose that D2 might function as an auxiliary cat-
alytic site that would be activated under specific cellular con-
ditions or in the presence of a proper substrate (23).
A generalized model, known as the dimeric inhibition
model or the wedge hypothesis, for the regulation of RPTP
activity has been proposed based on the crystal structure of
the RPTP
 
  
 
D1 domain (26). The RPTP
 
  
 
D1 domain
formed a homodimeric structure in the crystal, in which the
active site of one monomer was blocked by an NH
 
2
 
-termi-
nal helix-turn-helix wedge motif of the other monomer,
suggesting that dimer formation on the membrane nega-
tively regulates the PTP activity. Experimental data that
seem to corroborate this model have been reported. For ex-
ample, ligand-induced dimerization of the epidermal growth
factor receptor–CD45 chimeric molecule and enforced co-
valent dimerization of full-length PTP
 
  
 
resulted in down-
regulation of their PTP activities (27, 28). Impairment of
dimer formation, by introducing mutations into the wedge
region, led to apparent PTP activation both in vivo and in
vitro (28–30). Transiently expressed PTP
 
  
 
was shown to ex-
ist predominantly as homodimers (31). In the same study,
however, mutations in the wedge region reduced but did
not completely abolish PTP
 
  
 
dimerization, suggesting that
other factors are also contributing to the dimer formation.
Here, we report crystal structures of the CD45 cytoplas-
mic region containing both the D1 and D2 domains. We
also determined crystal structures of the CD45 cytoplasmic
region bound to phosphopeptide substrates; one bound to a
nonspecific short phosphopeptide, and the other bound to
the membrane-proximal immunoreceptor tyrosine-based ac-
tivation motifs (ITAMs) of the CD3
 
  
 
chain. We will de-
scribe the key features of CD45 and its substrate interactions
and discuss the implications of these structures as they impact
on our understanding of the mechanism of D1 and the po-
tential function of D2. In these structures, CD45 exists as a
monomer with the D1 active site cleft, as well as the D2 site,
clearly unobstructed by the rest of the protein chain. The
observed intramolecular orientation of the D1 and D2 do-
mains precludes the formation of a dimer of the type pre-
dicted by the dimeric inhibition model. Such a D1 dimer in-
teraction is impossible because of significant steric hindrance
generated from the overlap of the attached D2 domains.
 
RESULTS
Overview of the CD45 D1D2 structure determination
 
In human leukocytes, various CD45 isoforms of different
lengths are expressed by combinatorial alternative splicing
(15). All isoforms, however, share the exactly identical cyto-
plasmic region of 707 amino acids, which is composed of a
Figure 1. The overall structure of the CD45 molecule and the 
amino acid sequence of the CD45 D1D2 domains. (A) A schematic 
model of the human CD45 molecule. Numbers in parentheses are amino 
acid positions. In this work, we refer to the amino acid positions as they 
appear in the mature protein of the longest isoform (reference 15). FNIII 
domain, fibronectin III–like domain. (B) The segment of the CD45 cyto-
plasmic region whose structure is described here is shown as primary 
sequence. The D1 and D2 sequences are aligned according to their second-
ary structures. The secondary structure elements are represented as green 
bars for   helices and red arrows for   strands on top of the amino acid 
sequence. The wedge region, the KNRY motif, the WPD motif, the PTP sig-
nature motif, the Q-rich motif, and the interdomain linker region are 
marked by yellow overlay. The acidic and basic loops are marked by magenta 
and blue overlays, respectively. 
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juxtamembrane spacer segment, the PTP D1 domain, a short
interdomain linker, the PTP D2 domain, and a COOH-ter-
minal tail (Fig. 1 A). In this report, we will refer to the amino
acid positions as they appear in the mature protein of the
longest isoform (15). According to this convention, the cyto-
plasmic domain is from 575 to 1281, and the catalytic site
cysteine residues are at 828 (Cys828) in D1 and at 1144
(Cys1144) in D2, respectively. An alignment of the D1 and
D2 sequences, as well as several key features in the PTP do-
main, are shown in Fig. 1 B. Previously, we and others have
shown that the CD45 D2 PTP domain has no catalytic activ-
ity (16, 32), whereas others reported different findings (33).
Later in this report, we will present the structural basis of why
the CD45 D2 domain cannot have a catalytic activity. For
convenience sake, however, we will use terms such as “D2
active site,” “D2 catalytic site,” etc., to refer to the region in
D2 that corresponds in PTP domain structure to the D1 ac-
tive site, without implying an actual catalytic activity.
To obtain the materials for crystallographic studies, the
CD45 cytoplasmic region containing both the D1 and D2
domain was expressed in 
 
Escherichia coli
 
 as six-His–tagged
proteins and purified to apparent homogeneity. In our initial
attempts where we used the entire cytoplasmic region of
CD45, we could not obtain sufficiently good crystals. This
was likely due to the presence of an extended COOH-ter-
minal segment that seems flexible. To circumvent this prob-
lem, we generated a series of CD45 cytoplasmic fragments,
differing both at the NH
 
2
 
- and COOH-terminal positions,
to obtain the optimal domain boundaries for crystallization.
Thus, we obtained two different crystals, CD45 D1D2
(597–1213) with Cys828 to Ser (C828S) mutation, and
wild-type CD45 D1D2 (603–1203), which gave optimal
diffraction data. In addition, a number of datasets were ana-
lyzed from crystals grown in the presence of different ions
(sulfate, phosphate, and tungstate ions), monomeric phos-
photyrosine, and two different phosphotyrosyl-peptides.
The best quality data have been collected from mono-
clinic crystals of selenomethionine (Sel-Met)–substituted
CD45-D1D2 (597–1213) (C828S) protein with phosphoty-
rosine-containing peptides (derived from polyoma middle T
antigen and CD3
 
  
 
ITAM motif; see below for more details).
The crystal structures for both complexes were solved to 2.9
Å resolution by the molecular replacement method. Data
collection and the final refinement statistics for these com-
plexes are summarized in Table I. Both datasets are of similar
quality with respect to resolution and agreement of R factor
for symmetry-related reflections (R
 
sym
 
). The corresponding
protein structures demonstrate correct geometric parameters
as well as the desired lack of model bias. The current CD45
model includes 589 residues (601–1205), excluding the dis-
ordered acidic loop segment of D2.
In Fig. 2, the structure of the CD45 cytoplasmic region
is viewed from three directions. For comparison, the struc-
ture of LAR D1D2, the only other RPTP for which the
tandem PTP domain structure has been solved (23), is repro-
duced in the inset as viewed from the same direction as the
CD45 structure shown at the top left. It is clear that the ob-
served orientation of the D1 and D2 domains in CD45 is
very similar to that adopted by LAR. It also can be seen that
the overall structures of the D1 and D2 domains are essen-
tially identical to each other. Both D1 and D2 domains con-
sists of a highly twisted nine-stranded mixed 
 
  
 
sheet flanked
 
Table I.
 
Crystallographic data and refinement statistics
 
CD45 D1D2 C828S and phosphopeptide complexes
Polyoma middle T antigen CD3 
 
 
 
ITAM-1
 
Crystallographic data
Space group P2(1) P2(1)
Cell parameters a 
 
  
 
86.9 Å, b 
 
  
 
57.9 Å
 
,
 
c 
 
  
 
159.3 Å
 
, 
 
  
 
=
 
 98.78
a 
 
  
 
86.0 Å, b 5 59.7 Å
 
,
 
c 
 
 
 
 160.5 Å, 
 
 
 
 5 99.58
Z4 4
X-ray source X12, BNL X12, BNL
Resolution 30–2.9 Å 30–2.9 Å
Observations (
 
n
 
) 99,669 99,514
Unique reflections (complete) 32,025 (93.0%) 29,466 (81.5%)
R
 
sym
a
 
0.079 0.071
Refinement statistics of current model
Resolution 30–2.9 Å 30–2.9 Å
Protein atoms (
 
n
 
) 9,457 9,416
Substrate atoms (
 
n
 
) 74 122
R
 
cryst 
 
(work
 
b
 
/free
 
c
 
) 0.263/0.306 0.258/0.315
Rmsd bond lengths 0.010 Å 0.010 Å
Rmsd bond angles 1.59
 
 
 
1.57
 
 
 
a
 
R
 
sym 
 
   
 
h 
 
 
 
i
 
|I
 
ih 
 
  
 
<I
 
h
 
>|/
 
 
 
h 
 
  
 
i
 
<I
 
h
 
>, where <I
 
h
 
> is the mean of the observations I
 
ih 
 
of reflection h.
 
b
 
R
 
working 
 
   
 
||F
 
obs
 
| 
 
  
 
|F
 
calc
 
||/
 
 
 
|F
 
obs
 
|.
 
c
 
R
 
free 
 
  
 
R factor for a selected subset (5%) of the reflections that was not included in prior refinement calculations. 
STRUCTURE OF THE TANDEM PTP DOMAINS IN RPTP CD45 | Nam et al.
 
444
 
by four 
 
  
 
helices on one side and two 
 
  
 
helices on the other.
In general, this domain structure is similar to those of previ-
ously reported PTPs (26, 34, 35). Secondary structure ele-
ments in D1 and D2, as determined in our structure, are
shown in Fig. 1 B.
 
Interaction of phosphopeptides at the D1 active site
 
To understand the mechanisms of substrate recognition and
dephosphorylation by CD45, purified CD45 D1D2 (597–
1213) C828S was crystallized in the presence of either phos-
photyrosine (i.e., monomeric amino acid) or one of two dif-
ferent phosphopeptides. C828S mutant was used to prevent
dephosphorylation of the substrates.
The first phosphopeptide (QQQQNQLpYNELNLGR-
REEpYDVLDKRRG, where pY is phosphotyrosine) is the
membrane proximal ITAM of the CD3
 
  
 
chain (
 
 
 
ITAM-1)
with both the tyrosine residues phosphorylated. CD3
 
  
 
is an
important CD45 substrate and contains three ITAMs in its
cytoplasmic domain. An ITAM is defined as a 20–25–amino
acid sequence containing two YxxL/I segments separated by
six to eight amino acid residues (36). Each of the three
ITAMs in CD3
 
  
 
is tyrosine phosphorylated when TCR is
activated. The doubly phosphorylated ITAMs serve as dock-
ing sites for the tandem SH2-containing ZAP-70, which ini-
tiates a cascade of signal transduction events (37, 38). It has
been demonstrated that CD3
 
  
 
and CD45 physically associate
in vivo and that CD45 efficiently dephosphorylates CD3
 
  
 
in
vitro (39, 40). Mutational analyses of the tyrosine residues in
the membrane-proximal ITAM of CD3
 
  
 
have shown that
the two YxxL segments in the ITAM are functionally dis-
tinct (41), indicating the critical importance of regulating
ITAM phosphorylation states.
The second phosphopeptide (NPTpYS) is derived
from the polyoma middle T antigen. Although this peptide
is probably not a physiologically meaningful substrate of
CD45, it has the advantage of being a well-known short
phospho-substrate.
When CD45 was crystallized in the presence of mono-
meric phosphotyrosine, there was a well-defined density cor-
responding to this moiety in the D1 active site pocket, but
no comparable density in the D2 domain that would suggest
the presence of phosphotyrosine (not depicted). In the crystal
structure of the CD45 D1D2 complexed with 
 
 
 
ITAM-1, al-
though there are two phosphotyrosyl residues in 
 
 
 
ITAM-1,
assignable extra densities were visible only at the D1 active
site. No extra densities are discernible at the D2 active site,
or in fact anywhere else associated with the protein. Electron
densities for six amino acids surrounding the second phos-
photyrosyl residue (REEpYDV) are visible at the D1 active
site (Fig. 3, A and B). This result appears consistent with the
Figure 2. Ribbon diagram representations of the CD45 D1D2
domains. Three different views are shown of the CD45 structure. The D1 
and D2 domains are shown in yellow and green, respectively. On the top 
left, the viewer is looking straight into the D1 active site, and the corre-
sponding active site of D2 is facing upward (y direction). For comparison, a 
corresponding diagram of LAR D1D2 is shown in the boxed inset. Two
additional views of CD45 molecule are generated by rotating the molecule 
by 90  along the horizontal axis in both directions (top right and bottom 
left). The secondary structure elements in D1 and D2 are labeled, respec-
tively, in the top left and top right panels. The acidic and basic loops are 
shown in magenta and blue, respectively. The wedge region is also shown. 
JEM VOL. 201, February 7, 2005
 
445
 
ARTICLE
 
previous in vitro analyses showing that the CD45 phos-
phatase prefers the second phosphotyrosine in 
 
 
 
ITAM-1
over the first phosphotyrosine (42). Similarly, in the structure
of CD45 bound with the polyoma phosphopeptide (NPT-
pYS), electron density corresponding to four residues (PT-
pYS) was visible only at the D1 active site (Fig. 4, A and B).
For both the 
 
 
 
ITAM-1 peptide and the polyoma pep-
tide, the general features of the phosphotyrosine binding to
the CD45 D1 active site are similar. The active site pocket of
CD45 D1 is composed of a base formed by the residues of
the PTP signature motif, surrounded by three additional seg-
ments: the KNRY motif, the WPD motif, and the Q-rich
motif (Fig. 1 B). Extensive hydrogen bonding occurs be-
tween the phosphotyrosyl residue and the active site pocket.
Within the PTP signature motif, the active site Cys828 (Ser
in our structure) is positioned for nucleophilic reaction with
the substrate phosphorus. Hydrogen bonds are observed be-
tween the phosphoryl moiety and the main chain amide
groups of the PTP signature motif, as well as the basic side
chain of Arg834. The tyrosine residue of the phosphopep-
tide is stabilized by aromatic ring stacking with Tyr658 in
the KNRY motif. The WPD motif, which contains catalyti-
cally important Asp796, adopts an open conformation when
crystallized with sulfate ions. This loop, however, shows a
closed conformation in all of our substrate-bound structures.
The imidazole ring of His797 makes hydrophobic contact
with the phenyl ring of the substrate phosphotyrosyl residue
as well as a hydrogen bond with the backbone carbonyl
group of the phosphotyrosyl residue. The acidic side chain
of Asp660 in the KNRY loop is making a hydrogen bond
with the amide group of the pY
 
 
 
1 residue. This positioning
of the two residues of opposite charges (His797 and Asp660)
seems to determine the backbone configuration of the sub-
strate phosphotyrosyl residue and residues COOH-terminal
to it. The conserved Gln872 and Gln876 residues in the
Q-rich motif are positioned surrounding the active site to
generate the required charge distribution and pocket shape
that accommodate a phosphate leaving group during cataly-
sis. Overall, most interactions between the substrate phos-
photyrosyl residue and the D1 active site are similar to those
seen in the substrate-bound complexes of PTP1B and 
 
Yersinia
 
PTP (43, 44), with the exception of the one between the
Figure 3. Structure of the CD45 D1D2 bound to the CD3  ITAM-1 
phosphopeptide. (A) A stereo view of the D1 active site with the CD3 
 ITAM-1 phosphopeptide. Relevant hydrogen bonds between the side 
chains of the CD45 protein and the ITAM-1 peptide are shown by green 
lines. (B) The phosphopeptide model is shown with a 2|Fobs| |Fcalc| com-
posite omit map at the 0.9   contour level. (C) Molecular surface repre-
sentation of the D1 active site bound to the CD3  ITAM-1 peptide. The 
surfaces are colored according to the electrostatic potential: blue for 
positive and red for negative. The peptide model is shown using a ball and 
stick representation. 
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carbonyl of the phosphotyrosyl residue and the basic side
chain of His797. The residue corresponding to His797 is a
phenylalanine in PTP1B. In the CD45 structure, His797
may add extra interactions and strengthen the binding of the
substrate phosphotyrosyl residue.
Fig. 3 A shows detailed interactions between six amino
acids (REEpYDV) of the 
 
 
 
ITAM-1 substrate and the CD45
protein. On the NH
 
2
 
-terminal side of the phosphotyrosyl
residue, the Glu (pY-1) side chain is pointing in the direc-
tion opposite that of the phosphotyrosine. The Glu (pY-1)
side chain is exposed to solvent without any interaction with
the protein; thus, the presence of a hydrophilic residue at
this position might be favored for binding. The carboxyl
group of the Glu (pY-2) makes a hydrogen bond contact
with the guanidium group of Arg734. The surface charge
distribution of the CD45 protein at this region shows an ex-
tended positively charged surface contributed by residues
Arg657, Arg704, Arg734, and Lys736 (Fig. 3, A and C). The
negatively charged Glu (pY-2) fits nicely into this positively
charged pocket and seems to be important for binding to the
CD45 PTP. The positive charges of the protein at this re-
gion may repel the basic side chain of Arg (pY-3), thus al-
lowing no direct interactions with the protein.
On the COOH-terminal side of 
 
 
 
ITAM-1, the Asp
(pY
 
 
 
1) side chain points toward the CD45 protein and
makes a hydrogen bond with the side chain of Gln872. The
main chain backbone of the Val (pY
 
 
 
2) runs almost perpen-
dicular to the rest of the peptides. The overall extent of these
contacts between the 
 
 
 
ITAM-1 substrate and the D1 domain
is consistent with the previous results from PTP1B–substrate
complexes (43), indicating that residues between pY-3 and
pY
 
 
 
2 of the substrate determine phosphatase specificities.
In the structure of CD45 bound with the polyoma phos-
phopeptide (NPTpYS), electron densities corresponding to
four residues (PTpYS) are visible at the D1 active site (Fig.
4). In addition to the interactions between the phosphoty-
rosine moiety and the protein, the NH
 
2
 
-terminal peptide
residues make contact with the KNRY loop. Thr (pY-1) is
in van der Waals contact with the side chain of Asp660, and
the ring of Pro (pY-2) is making a van der Waals contact
with the Tyr658 ring. The terminal oxygen of Ser (pY
 
 
 
1) is
hydrogen bonded with the side chain of residue Gln872 in
the Q-rich motif.
Based on these structures, we propose that the optimal
interaction of CD45 active site and phosphotyrosyl substrate
occurs when a hydrophilic residue occupies the pY-1 posi-
tion and negatively charged amino acids are located around
the pY-2 position. The Lck and Fyn protein tyrosine ki-
nases, two of the best known CD45 substrates, fit into these
criteria. These protein kinases have two tyrosine phosphory-
lation sites: one in their activation loops (DENEpYTAR in
Lck and EDNEpYTAR in Fyn) and another near their
COOH termini (TEGQpYQPQ in Lck and TEPQpYQPG
in Fyn). All of these peptides contain hydrophilic residues at
the pY-1 position, as in the 
 
 
 
ITAM-1 sequence. In the acti-
vation loop peptides, the acidic amino acid at pY-3 (and per-
haps at pY-4) is likely to interact with the positively charged
pocket of CD45. In the COOH-terminal peptides, we can
more confidently speculate that the negatively charged Glu
(pY-3) interacts with the positively charged pocket of
CD45, because the residues at the Y-2 position, namely Gly
and Pro, are optimal at generating conformations to accom-
modate such interactions. The NH
 
2
 
-terminal phosphoryla-
tion site of 
 
 
 
ITAM-1 (NQLpYNE) lacks these criteria. The
presence of the hydrophobic Leu residue at the pY-1 posi-
tion, and lack of any negatively charged amino acids at the
pY-2 and pY-3 positions, explain the reduced affinity of the
NH
 
2
 
-terminal phosphorylation site for the CD45 PTP.
 
The CD45 D2 domain is a totally inactive phosphatase
 
The strong structural conservation of the CD45 D2 domain
implies that it serves a cellular function, but it is still of ma-
Figure 4. Structure of the CD45 D1D2 bound to NPTpYS. (A) A stereo 
view of the D1 active site with the NPTpYS peptide. Relevant hydrogen 
bonds between the side chains of the CD45 protein and the NPTpYS pep-
tide are shown by green lines. (B) The phosphopeptide model is shown 
with a 2|Fobs| |Fcalc|composite omit map at the 0.9   contour level. 
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jor mystery. Our CD45 structure suggests that the function
of the CD45 D2 domain is very different from its LAR
counterpart. In the LAR D1D2 structure we determined
previously, the inactive D2 domain maintains an active site
topology similar to that of D1. With only two substitutions
of the key residues in the surrounding loops, LAR D2 could
be converted to a very active enzyme (23). In contrast, the
PTP signature motif in CD45 D2 deviates from the consen-
sus sequence to the extent that it can no longer accommo-
date a phosphoryl group (VHCSAGVGRTG in D1 vs. IH-
CRDGSQQTG in D2). As a result, the CD45 D2 domain
has a significantly reduced number of available ligands for
oxygen binding, a significantly altered shape of the active
site pocket, as well as a reduced accessibility of the Cys nu-
cleophile. Fig. 5, A and B, show the details of the D1 and
D2 active sites, respectively. In catalytically active PTP
structures, including the CD45 D1 domain, the side chain
of the highly conserved Arg in the PTP motif makes two
hydrogen bonds with the phosphoryl group and is very im-
portant for both substrate binding and transition state stabi-
lization (43). The fatal substitution of this Arg to Gln in
CD45 D2 (Gln1150) results in a shorter side chain that is
unable to interact with a phosphoryl group in the same
manner as Arg834 in D1. In addition, as shown in Fig. 5 B,
the bulky side chains of Asp1146 and Gln1149 are protrud-
ing toward what would have been the phosphoryl group
binding site. The N
 
 
 
1 of Asp1146 is also making a hydro-
gen bond with a backbone amide group, blocking the po-
tential binding partner of the phosphoryl group. Finally, the
presence of the negative charge at Asp1146, together with
the lack of a positively charged amino acid at 1150, must re-
pel any incoming phosphoryl group. Thus, it is apparent
that the deviations from the consensus at three positions
(Asp1146, Gln1149, and Gln1150) will abolish any affinity
for an incoming phosphoryl group. Indeed, despite a signif-
icant molar excess of the potential small molecule substrates
present in the crystallization trials, there is no evidence of
their presence in any of the CD45 D2 domains in any of the
crystal forms obtained.
The structure of the loops surrounding the D2 active
site is also quite different from that of the D1 active site.
This can be easily visualized by the surface representation of
the active sites with their respective charge distributions
(Fig. 5, C and D). The WPD loop in D2 shows a partially
open conformation, and the invariant Asp, which acts
as general acid/base in active PTPs, is substituted with
Val1102 in D2. This substitution will certainly impair cata-
lytic activity. The KNRY loop also shows a quite different
conformation in D2. The conserved Tyr involved in the
stabilizing   –   interactions with the phenyl ring of the
ligand phosphotyrosyl residue is replaced by Asn949 in D2,
further contributing to the reduced affinity for phosphoty-
rosyl substrates. In conclusion, the CD45 D2 structure does
not have even the remotest possibility of retaining a cata-
Figure 5. Comparisons between the D1 and D2 catalytic centers. 
(A and B) Ribbon diagrams of active sites in D1 (A) and D2 (B). Side chains 
of residues implicated in catalysis are shown. (C and D) Molecular surface 
of the active sites of D1 (C) and D2 (D), as seen from the same direction as 
in A and B. The surfaces are colored as in Fig. 3 C. Due to the closed con-
formation of the WPD loop in our structure, the surface charge distribu-
tion of the D1 active site pocket could not be easily viewed. To help show a 
comparison, the WPD loop of the D1 active site is presented in a partially 
open conformation in this figure, as was seen in the D2 active site.STRUCTURE OF THE TANDEM PTP DOMAINS IN RPTP CD45 | Nam et al. 448
lytic activity. This represents a clear mechanistic distinction
between CD45 and other RPTPs, even as compared with
its close relative, LAR.
Possible role of the CD45 D2 domain deduced 
from its structure
Inspection of the D2 structure, as detailed in this section,
suggests that it has a role in substrate recruitment. The CD45
D2 domain has two unique features that are not found in
any other PTPs, including LAR. Those are the two extra
loops, referred to, respectively, as the acidic and basic loops,
whose positions are shown in Fig. 2 by color. The 20–amino
acid acidic loop (SKESEHDSDESSDDDSDSEE [969–988]),
located between the  1 and  2 strands, is mostly disordered
and flexible. Although not all of the residues in the acidic
loops could be seen in the crystal structure, the location and
approximate model can be visualized based on the rest of the
structure and the electron density observed in this area. The
11–amino acid basic loop (KNSSEGNKHHK [1126–1136])
is located between the  3 helix and the  12 strand. The en-
tire basic loop could be refined in one of the two molecules
in the P2(1) space group, but the temperature factor for
these residues is quite high (average main chain B factor is
 20 Å2 higher than the rest of the molecule), reflecting the
flexible nature of the basic loop.
It has been reported that deletion of the acidic loop, or
substitution of four Ser residues to Ala in the acidic loop, di-
minished CD3-mediated activation of T lymphocytes (45).
Furthermore, phosphorylation of Ser residues in the acidic
loop by casein kinase 2 is important for CD45 functions
(21). Our structure lends a mechanistic explanation to such
observations. Both the acidic and basic loops in D2 are lo-
cated on the same side of the surface of the molecule with
respect to the D1 active site. Because both loops have signif-
icant charge biases and are located very close to the active
site in D1, they could easily serve as initial substrate recruit-
ing sites. When phosphorylated, these loops may undergo a
conformational change or induce a change in the catalytic
site to facilitate docking of incoming substrates.
Extensive interaction between the D1 and D2 domains
In this work, we obtained crystals of CD45-D1D2, without
peptide, in two different space groups: P2(1) and P6(3)22.
Although the crystallographic contacts between the neigh-
boring molecules are totally different in the two crystal
forms, the intramolecular spatial relationship between the
D1 and D2 domains is essentially identical in both crystal
forms. Several cocrystals of CD45-D1D2 with phosphopep-
tides also had very similar D1–D2 domain orientation. If the
atoms of the D1 domains from two different crystal forms,
P2(1) and P6(3)22, are superimposed, the atoms in the D2
domains differ by an average (root-mean-square) distance of
3.2 Å between the equivalent C  atoms. They differ by 2.9
Å between the two noncrystallographically related molecules
in the P2(1) space group. The average distances are even
smaller between the residues located at the interface of the
D1 and D2 domains ( 1.5 Å). In all cases, the D1 and D2
domains are connected by a four-residue linker, GETE
(891–894), and packed tightly against each other. This link-
ing segment is conserved between CD45 and LAR (GETE
and GHTE, respectively) and is bound to both D1 and D2
domains in a similar fashion in the two different proteins.
The interdomain orientation between D1 and D2 is further
stabilized by an extensive network of interactions, consisting
of hydrogen bonds, van der Waals interactions, and salt
bridges (Fig. 6). Hydrophobic interactions were observed at
two regions of the interdomain surface. Phe890 at the end of
D1  6 is making van der Waals contact with the Phe1173 in
D2  5, and Pro765 (in the loop between  9 and  10 of D1)
is in contact with Tyr1001 and Trp1002 (in the loop be-
Figure 6. Intramolecular interactions between the D1 and D2 
domains. The circled region of the small diagram on the left shows the 
interface between the D1 (yellow) and D2 (green) domains. The detailed 
view of this area, rotated 60 , along the horizontal axis is shown on the 
right. Amino acid residues involved in interdomain interactions are shown 
with carbon in yellow, oxygen in red, and nitrogen in blue. Selected hydro-
gen bonds are shown by red dotted lines.JEM VOL. 201, February 7, 2005 449
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tween  2 and  3 of D2). Hydrophobic interactions are fur-
ther stabilized by salt bridges, observed between the basic
side chains (His804, Lys808, Arg811, and Arg812) in D1  3
and acidic side chains (Glu1167 and Asp1171) in the D2 do-
main. Among these residues, Arg811 and Arg812 are highly
conserved among most RPTP D1 domains, and Glu1167
and Asp1171 are conserved in most RPTP D2 domains.
Overall, there are extensively complementary surfaces be-
tween the D1 and D2 domains, including the residues of the
 3 and  6 helices of D1 and the  4 and  5 helices of D2.
These results suggest that the intramolecular D1–D2 ori-
entation reported here is a likely state of the CD45 molecule
in the cell. Furthermore, this relative orientation of the D1
and D2 domains of CD45 is very similar to that of LAR,
which we reported previously (23), suggesting that this is
typical of most, if not all, two-domain RPTPs. The energy
required to separate D1 from D2 is  16 kcal/mol, which is
probably sufficient to keep the two domains bound together
even if they are not tethered by the linker. This conclusion is
consistent with the earlier observations, based on fluores-
cence resonance energy transfer and coprecipitation analyses,
which showed strong intermolecular and intramolecular in-
teractions between D1 and D2 domains of various RPTP
proteins (46, 47). Nonetheless, it should be noted that the
extracellular domain and transmembrane segment, which are
not included in our structure, may have a significant influ-
ence on the conformation of D1–D2 orientation in cells.
Because of these extensive D1–D2 interactions, even
subtle structural changes in D2 might affect the D1 confor-
mation. Indeed, a mutation in D2 is known (Q1180G in
mouse CD45, which is equivalent to Q1192G in our human
structure) that nearly completely abolishes the D1 catalytic
activity (48). Because Gln1192 is not making any direct con-
tact with D1 residues, its effect must be propagated indirectly
through the D1–D2 interface. Exactly how this is effected
will require the structural solution of the CD45 Q1192G
mutant protein. Thus, stabilization of the D1 domain seems
an important role of D2. We can hypothesize that the pri-
mordial two-domain RPTPs had two enzymatically active
PTP domains, and over the history of RPTP evolution, D1
and D2 domains established extensive association to the ex-
tent that one requires another for maintenance of its proper
structure. Thus, although the CD45 D2 domain has lost its
catalytic activity, it may still be needed to support the D1
structure and activity.
DISCUSSION
An outstanding question concerning RPTPs is how extra-
cellular stimuli, such as ligand binding, may affect the cata-
lytic activity of the cytoplasmic PTP domains. A major
model concerning this question was proposed based on the
crystal structure of the RPTP  D1 domain that crystallized
as a dimer (26). In the RPTP  dimer structure, the active
site in each monomer was blocked by the NH2-terminal
 1 -turn- 2   segment (called “wedge”) of an opposing
monomer, thus preventing substrate access to the active site.
It was further suggested that ligand-induced dimerization in-
activates the RPTP phosphatase activity. The wedge hy-
pothesis is aesthetically attractive because, if proven, it would
depict RPTPs as a perfect mirror image of receptor tyrosine
kinases, where ligand-induced dimerization typically acti-
vates the kinases. This hypothesis was apparently supported
by in vivo and in vitro analyses of RPTP  and epidermal
growth factor receptor–CD45 chimeric molecules (28–30).
Nonetheless, our present CD45 structure shows that the
cytoplasmic region of CD45 does not dimerize even when
highly concentrated, and the dimeric interaction as observed
for RPTP  D1 would be impossible given the D1–D2 in-
tramolecular domain orientation. The CD45 D1–D2 inter-
action seems too tight to allow the deformation needed for
D1–D1 interaction, given the extensive interface and the es-
sentially identical D1–D2 orientation observed among dif-
ferent CD45 crystal forms and LAR. Furthermore, the
CD45 wedge region (610–634; refer to Fig. 2) is not in-
volved in any intermolecular interaction. We previously
reached a similar conclusion regarding lack of dimerization
of the D1D2 domains based on the LAR structure (23). At
that time, we could not know for sure whether what we ob-
served for LAR represented a general phenomenon or
merely an isolated case of that particular RPTP. However,
now that we have solved the CD45 structure itself, we can
convincingly conclude that the steric hindrance from the D2
domain prevents D1–D1 dimer formation in CD45 as pro-
posed previously (26).
Our data, therefore, indicate that the regulation of CD45
cannot be simply explained by the dimeric inhibition model
mediated by the NH2-terminal wedge. Nonetheless, the
wedge region (helix-turn-helix motif) is conserved, suggest-
ing that it has a regulatory function (29, 30). If so, however,
it is likely that the wedge region influences the CD45 func-
tion by a mechanism other than the dimer formation. In-
deed, it was recently shown that CD45 could dimerize with-
out the cytoplasmic domain (49). Furthermore, a CD45
wedge mutation that had significant effect on the CD45
function did not affect the dimerization. Obviously, more
studies, including the structures of additional RPTPs as well
as the extracellular portion of CD45, will be needed to fur-
ther such understanding.
MATERIALS AND METHODS
Nomenclature. An individual amino acid is indicated by the standard
three-letter or one-letter code, followed by its amino acid position. Thus,
both Cys828 and C828 represent the cysteine at position 828. Missense mu-
tations are designated by the one-letter code. C828S, for example, indicates
the mutation of Cys828 to serine. Peptide sequences are indicated by the
one-letter amino acid code. pY is a phospho-tyrosine residue. pY-1 indi-
cates the amino acid position immediately on the NH2-terminal side of pY,
and pY 2 represents the second amino acid from pY on the COOH-ter-
minal side.
Preparation of recombinant proteins. Proteins were expressed using
the T7 expression system essentially as described previously (23, 50). The
catalytic site mutant (C828S) of CD45-D1D2 (597–1213) was tagged at the
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(603–1203) was tagged with noncleavable COOH-terminal six-His. The
proteins were first purified using a Ni-affinity column (and in the case of the
cleavable tag, six-His was removed by the TEV protease). The proteins
were further purified using an anion exchange column. After desalting, the
proteins were concentrated to 10 mg/ml. For expression of Sel-Met–substi-
tuted protein, the methionine auxotrophic strain E. coli B834 (DE3) was
used. The transformed cells were grown in the M9 medium supplemented
with 40 mg/ml L–Sel-Met and 19 other amino acids. Purification was per-
formed following the similar procedure as the native protein.
Crystallization. Two different crystal forms of CD45 D1D2 protein were
obtained. Monoclinic crystals of CD45-D1D2 (597–1213) C828S were
grown by vapor diffusion in hanging drops in 100 mM sodium acetate, pH
5.0, 10–13% (wt/vol) polyethylene glycol (PEG) 4000, 10 mM dithiothrei-
tol (DTT), and 25% glycerol, with various additives such as ammonium sul-
fate, phosphotyrosine, or phosphopeptide. For cocrystallization experiments
with phosphopeptides, either NPTpYS derived from polyoma middle T
antigen or QQQQNQLpYNELNLGRREEpYDVLDKRRG, the mem-
brane proximal ITAM of the CD3  chain ( ITAM-1), was added to the pu-
rified CD45-D1D2 (597–1213) (C828S) protein so that the final concentra-
tion of the peptides would be  10 mM.
Hexagonal crystals of CD45-D1D2 (603–1203) with noncleavable
COOH-terminal six-His tag were grown by vapor diffusion in hanging
drops in 100 mM MOPS/NaOH, pH 6.5, 13–15% (wt/vol) PEG 8000, 0.5 M
ammonium sulfate, 10 mM DTT, and 15% glycerol.
X-ray data collection. Crystals were flash-frozen with the crystallization
solution. Diffraction data were collected at various synchrotron sources in-
cluding the F1 station of the Cornell High Energy Synchrotron Source, the
SBC-CAT of Advanced Photon Source in Argonne National Laboratory,
and the X12 station of Brookhaven National Laboratory (BNL). Images
were processed with DENZO, and data were scaled and processed with
SCALEPACK (51).
Structure determination. Initially, the structure of CD45-D1D2 (597–
1213) C828S bound with sulfate ion was determined. In this crystal form,
two molecules were expected in an asymmetric unit. The structure was de-
termined by molecular replacement using an unaltered model of the D2 do-
main of RPTP LAR as a search model with the program AmoRe (52). An
initial search revealed four unambiguous positions of phosphatase domains.
After rigid body refinement, the identity of the PTP domains was deter-
mined based on the locations of the N and COOH termini, and amino acid
sequence was changed to reflect the CD45 molecule. Several iterative cycles
of refinement were performed using minimization and anisotropic tempera-
ture factor refinement options of the crystallography & NMR system
(CNS) software packages, followed by manual rebuilding (53). Noncrystal-
lographic symmetry restraints were used throughout refinement. Composite
omit map in CNS was used for most of the refinement steps.
A refined model of the CD45-D1D2 (597–1213) C828S–sulfate com-
plex was then used to determine other crystal structures. A Sel-Met dataset
was collected with the intention of confirming the refined structure. Be-
cause of the anisomorphism, the Sel-Met data could not be used for phase
determination. Instead, an Fobs-Fcalc map was generated using the CD45-
D1D2 (597–1213) C828S model and Sel-Met data. The map showed strong
( 3.5 ) corresponding densities at most of the Met positions, validating the
structure. For structure determination of Sel-Met CD45-D1D2 (597–1213)
C828S–phosphopeptide complexes, a refined model of Sel-Met CD45-
D1D2 (597–1213) C828S was used to generate an Fobs-Fcalc map. For both
phosphopeptides,  ITAM-1 and polyoma middle T antigen, initial maps re-
vealed clear peptide density at each D1 active site. Refinement procedures
include minimization and individual temperature factor refinement using
the CNS software package.
In the hexagonal crystal of CD45-D1D2 (603–1203), one molecule
was expected in an asymmetric unit. For the structure determination, the
refined model of the CD45-D1D2 (597–1213) C828S was used for molec-
ular replacement. The CD45 D1 and D2 domains were used either together
or separately for the search. In both cases, the highest solutions were the
same, and the relative orientation of the D1 and D2 domains was basically
identical as in monoclinic crystals.
Calculation of the free energy required to separate the D1 and D2
domains. Environment-free energies of the CD45 D1D2 proteins have
been calculated using the program ENVIRON (54). The atomic model of
the protein was manually modified so that there were no interdomain inter-
actions between the D1 and D2 domains, with the linker region still at-
tached. The environment-free energies of the several modified models were
calculated, and the energy required for separation of the D1 and D2 do-
mains was calculated by subtracting the free energy of the native protein
from that of the modified proteins.
Coordinates of the CD45/CD3  ITAM-1 and the CD45/polyoma
middle T antigen complex have been deposited into the Protein Data Bank
with the ID clones IYGR and IYGU, respectively.
Graphics. Molecular models were generated using the programs AL-
SCRIPT (55), MOLSCRIPT (56), RASTER3D (57), BOBSCRIPT (56,
58), and GRASP (59).
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